Infant Bacterial Therapeutics   Report issue

For profit Phase 3
Founded: Stockholm Sweden (2013)

Organization Overview

First Clinical Trial
2016
NCT02472769
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Infant Bacterial Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

lactobacillus reuteri (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Enterocolitis (Phase 3)

Enterocolitis, Necrotizing (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1